US 2017/0281628 A1 · MOLECULAR TARGETS FOR THE TREATMENT OF WOUNDS, IN PARTICULAR CHRONIC WOUNDS

Molecular targets for the treatment of wounds, in particular chronic wounds

AssigneesUrgo Recherche Innovation Et Developpement, Centre National de la Recherche Scientifique (CNRS), Universite Paris Diderot—Paris 7, Inserm (Institut National De La Sante Et De La Recherche Medicale), Ecole Normale Superieure

InventorsClaire Dugast-Darzacq, Maite Noizet, Xavier Darzacq, Beatrice Spiluttini Hebert

Life of this patent

Estimating the term…

Abstract

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREBS, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.

Claims20

Dependent claims

A method for treating wounds, preferably chronic wounds, in a subject in need thereof, comprising administering to said subject a therapeutic compound comprising:

an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2, and homologues thereof having at least 50% identity with said genes
and/or
an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9, preferentially FOXS1, EGR2, SOX9, TCF4, STAT4 and homologues thereof having at least 50% identity with said gene.

Dependencies are inferred from the claim text.

Facts

Application

14/909,669Filed 30 Jul 2014

Priority

5 Aug 2013

Published

5 Oct 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61K 9/0014
Galenical forms characterised by the site of application: skin, i.e. galenical aspects of topical compositions
A61K 31/197
Having an amino group: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA],…
A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings